Alkermes Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Alkermes Plc (ALKS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Alkermes Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,668M vs 99,173M combined for its competitors (1.7% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+19.0% annualized vs trailing 12 months), vs accelerating (+6.2%) for its tracked peer group.
- Growth: Alkermes Plc generated 27.0% revenue growth year over year in Q2 2026, vs 43.3% for its competitors combined.
- Profitability: Its 0.1% net margin compares with 26.1% for the peer group.
- Scale: Alkermes Plc ranks #44 of 548 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.1% of industry market cap.
- Peer revenue share: Alkermes Plc accounted for 1.9% of combined revenue among its tracked peer group, down from 2.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.81M compares with $1.42M for the peer group (0.6x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ALKS Sales vs. its Competitors, Q2 2026
Alkermes Plc reported revenue growth of 26.97 % year on year in Q2 2026, below its competitors' combined revenue growth of 43.26 %.
With a net margin of 0.10 %, Alkermes Plc reported lower profitability than its competitors (26.14 %).
Alkermes Plc generated 1.85 % of the combined sales of its peer group, down from 2.08 % a year earlier.
Alkermes Plc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Alkermes Plc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Alkermes Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Alkermes Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Alkermes Plc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs 27.0% for Alkermes Plc. Alkermes Plc's share of combined industry revenue moved from 0.08% to 0.10%, a gain of 0.01 percentage points.
Alkermes Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Alkermes Plc | Yes | Yes | Yes | Yes |
| Competitors combined (37) | ||||
| High-Confidence Competitors (10) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ALKS Stock Performance relative to its Competitors
ALKS Stock Performance relative to High-Confidence Competitors
ALKS Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Climb Bio Inc | 282.9% | Outperformed |
| 2 | Gossamer Bio Inc | 282.9% | Outperformed |
| 3 | Eton Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Amylyx Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Amneal Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Alkermes Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Alkermes Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Alkermes Plc |
7,926.21 | 1,667.65 |
 Eli Lilly And Company |
1,259,140.09 | 86,462.00 |
 Biomarin Pharmaceutical Inc |
10,824.03 | 3,406.61 |
 Praxis Precision Medicines Inc |
8,171.64 | 8.55 |
 Axsome Therapeutics Inc |
7,321.87 | 865.27 |
 Amneal Pharmaceuticals Inc |
6,630.94 | 3,117.47 |
| SUBTOTAL | 1,323,495.40 | 101,012.94 |
Sign in to see all competitors of Alkermes Plc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Alkermes Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Alkermes Plc's Competitors Named by the Company
Competitive relationships identified from Alkermes Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Definium Therapeutics Inc | Company report | 85% |
| Centessa Pharmaceuticals Plc | Company report | 85% |
| MNMD | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Intra cellular Therapies Inc | Company report | 85% |
| Medicenna Therapeutics Corp. | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Opiant Pharmaceuticals Inc | Company report | 85% |
| Passage Bio Inc | Company report | 85% |
| Lyra Therapeutics Inc | Company report | 85% |
| Amneal Pharmaceuticals Inc | Company report | 85% |
| Harmony Biosciences Holdings inc | Company report | 85% |
| Adial Pharmaceuticals Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Sage Therapeutics Inc | Company report | 85% |
| Acadia Pharmaceuticals Inc | Company report | 85% |
| Axsome Therapeutics Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Karuna Therapeutics Inc | Company report | 85% |
| Indivior Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Alkermes Plc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Alkermes Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Biomarin Pharmaceutical Inc | Reportable 100.00 % |
| Amneal Pharmaceuticals Inc | Affordable Medicines 58.61 % |
| Indivior Pharmaceuticals Inc | Reportable 100.00 % |
| Acadia Pharmaceuticals Inc | Reportable Segment Aggregation Before Other Operating Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Alkermes Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Alkermes Plc | 7,926 | 813,489 | 32,255 |
| Eli Lilly And Company | 1,259,140 | 1,729,240 | 551,594 |
| Biomarin Pharmaceutical Inc | 10,824 | 1,057,626 | 22,655 |
| Praxis Precision Medicines Inc | 8,172 | 50,911 | -2,018,607 |
| Axsome Therapeutics Inc | 7,322 | 935,425 | -170,045 |
| Amneal Pharmaceuticals Inc | 6,631 | 366,762 | 25,332 |
| PEERS TOTAL | 1,315,569 | 1,424,019 | 378,094 |
Alkermes Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Alkermes Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 497 companies in Alkermes Plc's industry classification, broader than the peer set above. Market cap in millions of $.Alkermes Plc ranks #44 of 497 companies by market capitalization in its industry, holding 0.14 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 896, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,259,563 | 21.86 % |
| 2 | Johnson and Johnson | 649,481 | 11.27 % |
| 3 | Beone Medicines Ltd | 534,403 | 9.28 % |
| 4 | Abbvie Inc | 506,506 | 8.79 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 44 | Alkermes Plc | 7,926 | 0.14 % |
Market cap and industry share for the rest of Alkermes Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-03.
Alkermes Plc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 39 | Tg Therapeutics Inc | 9,555 | 76.48 % |
| 40 | Arrowhead Pharmaceuticals Inc | 8,535 | 42.37 % |
| 41 | Pharming Group N v | 8,524 | -3.47 % |
| 42 | Cytokinetics Incorporated | 8,230 | -0.61 % |
| 43 | Praxis Precision Medicines Inc | 1,234 | 12.3% |
| 44 | Alkermes Plc | 7,926 | 51.91 % |
| 45 | Legend Biotech Corporation | 1,234 | 12.3% |
| 46 | Kiniksa Pharmaceuticals International Plc | 1,234 | 12.3% |
| 47 | Redhill Biopharma Ltd | 1,234 | 12.3% |
| 48 | Axsome Therapeutics Inc | 1,234 | 12.3% |
| 49 | Ligand Pharmaceuticals Incorporated | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Alkermes Plc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-03. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Alkermes Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (339 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.85 % | 20.18 % (avg) | -19.3 pp |
| Operating Margin | 0.07 % | industry median | +0.1 pp |
| EBITDA Margin | 0.13 % | -3.03 % (avg) | +3.2 pp |
| Capital Intensity (Capex / Revenue) | - | 5.31 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Alkermes Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (339 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 28.4x | - |
| EV / EBITDA | 40.6x | 16.3x | +24.3x |
| P/B | 3.8x | 4.1x | -0.2x |
| Return on Equity | 0.04 % | industry aggregate | -17.11 % |
| Return on Invested Capital | - | -4.48 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Alkermes Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 24.60 % | 4.03 % | -11.29 % | 13.00 % | -5.28 % | 49.61 % | -6.36 % | -5.25 % |
| Operating Margin | -8.70 % | -14.99 % | -10.82 % | -2.50 % | -12.80 % | 32.35 % | 27.00 % | 17.21 % |
| Return on Invested Capital | -3.73 % | -7.02 % | -4.39 % | -1.11 % | -5.57 % | 18.94 % | 14.09 % | 7.19 % |
| P/E | - | - | - | - | - | 12.5x | 13.3x | 21.0x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Alkermes Plc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Alkermes Plc falls in the Dog quadrant: relative market share of 0.01x vs its largest competitor, in an industry growing revenue 7.5% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Alkermes Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 896 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Alkermes Plc's dedicated Suppliers and Customers pages, not here.
Alkermes Plc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Alkermes Plc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Alkermes Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+19.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 17.1 points below the industry aggregate.
- Low relative market share vs the industry leader (0.01x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (34.30 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Alkermes Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Alkermes Plc | 0.82 | 2.87 | 0.43 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Biomarin Pharmaceutical Inc | 1.41 | 4.08 | 0.30 |
| Praxis Precision Medicines Inc | 11.53 | 11.58 | - |
| Axsome Therapeutics Inc | 0.71 | 1.44 | 2.27 |
| Amneal Pharmaceuticals Inc | 0.26 | 2.23 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Alkermes Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Alkermes Plc | Q2 2026 | +27.0 % | -99.4 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Biomarin Pharmaceutical Inc | Q2 2026 | +19.9 % | -81.4 % |
| Praxis Precision Medicines Inc | Q2 2026 | - | - |
| Axsome Therapeutics Inc | Q3 2026 | +51.9 % | - |
| Amneal Pharmaceuticals Inc | Q2 2026 | +9.9 % | +95.5 % |
| PEERS TOTAL | +35.8 % | +18.1 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Alkermes Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Alkermes Plc | Q2 2026 | +98.4 % | -37.4 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Biomarin Pharmaceutical Inc | Q2 2026 | +35.1 % | +97.2 % |
| Praxis Precision Medicines Inc | Q2 2026 | - | +1,717.9 % |
| Axsome Therapeutics Inc | Q3 2026 | +49.5 % | +239.7 % |
| Amneal Pharmaceuticals Inc | Q2 2026 | +5.4 % | +354.5 % |
Alkermes Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Alkermes Plc | 1.96% | 2.31% | 3.72% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Biomarin Pharmaceutical Inc | 0.82% | 0.91% | 1.18% |
| Praxis Precision Medicines Inc | - | - | - |
| Axsome Therapeutics Inc | - | - | - |
| Amneal Pharmaceuticals Inc | 5.90% | 7.91% | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Alkermes Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Alkermes Plc | 50.83 | 4.75 |
| Eli Lilly And Company | 45.76 | 14.56 |
| Biomarin Pharmaceutical Inc | 154.61 | 3.18 |
| Praxis Precision Medicines Inc | - | 955.41 |
| Axsome Therapeutics Inc | - | 8.46 |
| Amneal Pharmaceuticals Inc | 41.24 | 2.13 |
| PEERS AVERAGE | 50.05 | 13.10 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.